Peptide Libraray

DAP2

General Information

DCTPep ID DCTPep01038

Peptide Name DAP2

Sequence RWGKWFKKNSHLS

Sequence Length 13

UniProt ID Not available

PubChem CID Not available

Origin Synthetic

Type Synthetic peptide

Classification

Cancer therapy related peptides

Activity Information

Cell Line	Disease	Activity	Assay	Testing Time	Literature
A549	Lung adenocarcinoma	IC50>100 µM	MTT assay	48h	1
NCI/ADR-RES	High grade ovarian serous adenocarcinoma	IC50>100 µM	MTT assay	48h	1
OVCAR-3	High grade ovarian serous adenocarcinoma	IC50>100 µM	MTT assay	48h	1
T24	Bladder carcinoma	IC50>100 µM	MTT assay	48h	1

Hemolytic Activity Not available

Normal (non-cancerous) Cytotoxicity HUVEC: IC50>100 μM; NL20: IC50>100 μM

Target Not available

Affinity Not available

Mechanism Not available

Structure Information

PDB ID Not available

Predicted Structure DCTPep01038

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity Not available

Linear/Cyclic Linear

Disulfide/Other Bond Not available

N-terminal Modification Free

C-terminal Modification Amidation

Other Modification None

Chiral L

Physicochemical Information

Formula C79H116N24O17

Absent amino acids ACDEIMPQTVY

Theoretical pI 11.26

Acidic residues 0

Basic residues 5

Polar residues 4

Molecular weight (Average) 1673.94

Molecular weight (Monoisotopic) 1672.89

Common amino acids K

Net charge 5

Instability index (II) 27.22

Aliphatic index 30.00

Grand average of hydropathicity (GRAVY) -1.546

Half Life
1 hours (mammalian reticulocytes, in vitro).
2 min (yeast, in vivo).
2 min (Escherichia coli, in vivo).

Extinction coefficients
Ext. coefficient 11000
Abs 0.1% (=1 g/l) 6.571

Amino acid distribution

Literature Information

Literature 1

Pubmed ID 33184577

Title Re-engineering Antimicrobial Peptides into Oncolytics Targeting Drug-Resistant Ovarian Cancers

Doi 10.1007/s12195-020-00626-z

Year 2020

Patent

Patent ID Not available

Patent Title Not available

Other Iinformation Not available

Other Published ID Not available